ARGOLYN BIOSCIENCE, INC.

Basic Information

ARGOLYN BIOSCIENCE, INC.
2750 Speissegger Drive, Suite 110
NORTH CHARLESTON, SC, -

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Development of Neurotensin-based Analgesics

    Amount: $163,945.00

    DESCRIPTION (provided by applicant): Chronic, neuropathic pain is one of the most important unmet medical needs in the United States, affecting tens to hundreds of millions of people nationwide at som ...

    SBIR Phase I 2006 Department of Health and Human Services
  2. Novel Neurotensin Analogs as Antischizophrenics

    Amount: $1,345,456.00

    DESCRIPTION (provided by applicant): Low levels of the brain peptide neurotensin (NT) have been linked to schizophrenia. Hence, stable NT receptor agonists that cross the blood brain barrier have sign ...

    SBIR Phase II 2005 Department of Health and Human Services
  3. NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT

    Amount: $125,279.00

    Argolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-n ...

    STTR Phase I 2002 Department of Health and Human Services
  4. NOVEL NEUROTENSIN ANALOGS AS ANTISCHIZOPRENICS

    Amount: $139,466.00

    DESCRIPTION (provided by applicant): The brain peptide neurotensin (NT) and its active derivative NT [8-13] function as endogenous neuroleptics. Stable NT derivatives that cross the blood brain barrie ...

    STTR Phase I 2002 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government